Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798695 | 0.88 | LIPC (0.37) | LIPCBRAFLIPGMMP13 | |
| SCHEMBL2797457 | 0.87 | METAP2 (0.38) | LIPCBRAFLIPGMMP13 | |
| SCHEMBL2794552 | 0.87 | LIPC (0.34) | LIPCBRAFLIPG | |
| SCHEMBL2795101 | 0.86 | LIPC (0.35) | LIPCBRAFLIPG | |
| SCHEMBL2797696 | 0.84 | LIPC (0.35) | LIPCBRAFLIPG | |
| SCHEMBL2798119 | 0.82 | MMP13 (0.34) | LIPCLIPGMMP13 | |
| SCHEMBL2799420 | 0.81 | MMP13 (0.33) | LIPCMMP13 | |
| SCHEMBL2798256 | 0.81 | MMP13 (0.33) | LIPCMMP13 | |
| SCHEMBL2798442 | 0.80 | NR3C1 (0.32) | LIPC | |
| SCHEMBL2799426 | 0.79 | NR3C1 (0.32) | LIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204365-A1 | ALKYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | BACE1, APP, AMY1A | LIPC 1380/4885BRAF 1162/4885LIPG 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.